Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The main purpose of this research study is to see if adding fulvestrant (Faslodex) to
erlotinib (Tarceva) is effective in patients with stage IIIb/IV Non-Small Cell Lung Cancer.